Mo Chen

Dr. Mo Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MCMo Chen
Mo Chen
SCSuyong Choi
Suyong Choi
TWTianmu Wen
Tianmu Wen
CCChangliang Chen
Changliang Chen
NTNarendra Thapa
Narendra Thapa
RARichard A. Anderson
Richard A. Anderson

2 November 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
NTNarendra Thapa
Narendra Thapa
MCMo Chen
Mo Chen
HHHudson T. Horn
Hudson T. Horn
SCSuyong Choi
Suyong Choi
TWTianmu Wen
Tianmu Wen
RARichard A. Anderson
Richard A. Anderson

14 April 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
XHXiaoting Hou
Xiaoting Hou
YCYu Chen
Yu Chen
NCNoah D. Carrillo
Noah D. Carrillo
VCVincent L. Cryns
Vincent L. Cryns
RARichard A. Anderson
Richard A. Anderson
MCMo Chen
Mo Chen
The cytoskeleton, composed of microfilaments, intermediate filaments, and microtubules, provides the structural basis for cellular functions such as motility and adhesion. Equally crucial, phosphoinositide (PIPn) signaling is a critical regulator of these processes and other biological activities, though its precise impact on cytoskeletal dynamics has yet to be systematically investigated. This review explores the complex interplay between PIPn signaling and the cytoskeleton, detailing how PIPn modulates the dynamics of actin, intermediate filaments, and microtubules to shape cellular behavior. Dysregulation of PIPn signaling is implicated in various diseases, including cancer, highlighting promising therapeutic opportunities through targeted modulation of these pathways. Future research should aim to elucidate the intricate molecular interactions and broader cellular responses to PIPn signaling perturbations, particularly in disease contexts, to devise effective strategies for restoring cytoskeletal integrity.

1 April 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
XHXiaoting Hou
Xiaoting Hou
CRChang Ren
Chang Ren
JJJing Jin
Jing Jin
YCYu Chen
Yu Chen
XLXinyu Lyu
Xinyu Lyu
MCMo Chen
Mo Chen

1 December 2023 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
CRChang Ren
Chang Ren
NCNoah D. Carrillo
Noah D. Carrillo
VCVincent L. Cryns
Vincent L. Cryns
RARichard A. Anderson
Richard A. Anderson
MCMo Chen
Mo Chen

9 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NCNoah D. Carrillo
Noah D. Carrillo
MCMo Chen
Mo Chen
TWTianmu Wen
Tianmu Wen
PAPoorwa Awasthi
Poorwa Awasthi
CSColin Sterling
Colin Sterling
RARichard A. Anderson
Richard A. Anderson
Summary: Phosphoinositide (PIP n ) messengers are present in non-membranous regions of nuclei where they are assembled into a phosphatidylinositol (PI) 3-kinase (PI3K)/Akt pathway that is distinct from the cytosolic membrane-localized pathway. In the nuclear pathway, PI kinases/phosphatases bind the p53 tumor suppressor protein (wild-type and mutant) to generate p53-PIP n complexes (p53-PIP n signalosome) that activate Akt by a PI3,4,5P 3 -dependent mechanism in non-membranous regions of the nucleus. This pathway is dependent on a source of nuclear PIP n s that is poorly characterized. Here we report that a subset of PI transfer proteins (PITPs), which transport PI between membranes to enable membrane-localized PIP n synthesis, also interact with p53 in the nucleus upon genotoxic stress. Class I PITPs (PITPα/β) specifically supply the PI required for the generation of p53-PIP n complexes and subsequent signaling in the nucleus. Additionally, the PI 4-kinase PI4KIIα binds to p53 and the PITPs to catalyze the formation of p53-PI4P. p53-PI4P is then sequentially phosphorylated to synthesize p53-PIP n complexes that regulate p53 stability, nuclear Akt activation and genotoxic stress resistance. In this way, PITPα/β and PI4KIIα bind p53 and collaborate to initiate p53-PIP n signaling by mechanisms that require PI transfer by PITPα/β and the catalytic activity of PI4KIIα. Moreover, the identification of these critical upstream regulators of p53-PIP n signaling point to PITPα/β and PI4KIIα as potential therapeutic targets in this pathway for diseases like cancer. In Breif: Phosphatidylinositol transfer proteins and a PI 4-kinase initiate nuclear p53-PIP n signaling in membrane-free regions.